查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1643920

全球麩質不耐症治療市場 - 2025-2032

Global Gluten Intolerance Treatment Market - 2025-2032
出版日期: | 出版商: DataM Intelligence | 英文 176 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

2024年，全球麩質不耐症治療市場規模達66.3億美元，預計2032年將達到161.8億美元，2024-2032年預測期間複合年成長率為11.8%。

麩質不耐症，也稱為非乳糜瀉麩質敏感性，是指個體在食用含麩質食物後出現腹部不適、腹脹和疲勞等症狀，但沒有患有乳糜瀉或小麥過敏的情況。與乳糜瀉不同，麩質不耐症不會對小腸造成損害，但仍會導致嚴重不適並影響生活品質。

麩質不耐症治療市場包括旨在緩解症狀和改善消化的治療方法，包括膳食補充劑、酵素療法和新興藥物選擇。隨著越來越多的人意識到麩質不耐症及其症狀，支持性治療和管理解決方案的市場正在擴大。

市場動態：

驅動程式和限制

麩質不耐症的診斷率不斷提高

診斷率的提高預計將導致更多的患者尋求醫療干預，從而推動麩質不耐症治療市場的發展。隨著醫療保健提供者和公眾對麩質不耐症和乳糜瀉的認知不斷增強，越來越多的人得到了準確診斷。診斷數量的增加意味著對有效治療方案的更大需求，例如酵素療法、補充劑和新興藥物療法。

此外，越來越多的確診患者正在積極尋求除嚴格的無麩質飲食之外的控制病情的解決方案，這推動了支持性治療市場的發展。隨著確診病例數持續上升，麩質不耐症治療的市場可能會大幅擴大。

飲食偏好和非醫療方法

飲食偏好和非醫療方法預計將阻礙麩質不耐症治療市場，因為許多人更喜歡透過無麩質飲食來控制自己的病情，而不是依賴藥物干預。無麩質飲食被廣泛認為是控制症狀的主要且最有效的方法，這使得許多患者不太願意尋求額外的治療，例如酵素補充劑或藥物。這種對飲食管理的依賴限制了市場對藥物治療的需求。

此外，個人可能認為非醫療方法（例如生活方式的改變）足以控制他們的病情，降低新療法的緊迫性，從而減緩市場成長。

目錄

第 1 章：方法與範圍

第 2 章：定義與概述

第 3 章：執行摘要

第 4 章：動力學

  • 影響因素
    • 促進要素
      • 麩質不耐症的診斷率不斷提高
    • 限制
      • 飲食偏好和非醫療方法
    • 機會
    • 影響分析

第 5 章：產業分析

  • 波特五力分析
  • 供應鏈分析
  • 定價分析
  • 專利分析
  • 監管分析
  • SWOT分析
  • 未滿足的需求

第 6 章：按治療類型

  • 飲食管理
  • 藥品
  • 營養補充品
  • 其他

第 7 章：按治療類型

  • 兒科
  • 成人
  • 老年科

第 8 章：按配方

  • 平板電腦
  • 粉末
  • 液體

第 9 章：按配銷通路

  • 網路藥局
  • 零售藥局
  • 電子商務

第 10 章：按地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 西班牙
    • 義大利
    • 歐洲其他地區
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美洲其他地區
  • 亞太
    • 中國
    • 印度
    • 日本
    • 韓國
    • 亞太其他地區
  • 中東和非洲

第 11 章：競爭格局

  • 競爭場景
  • 市場定位/佔有率分析
  • 併購分析

第 12 章：公司簡介

  • DSM-Firmenich
    • 公司概況
    • 產品組合
      • 產品描述
      • 產品關鍵績效指標 (KPI)
      • 歷史和預測產品銷售
      • 產品銷售
    • 財務概覽
      • 公司收入
      • 地域收入佔有率
      • 收入預測
    • 主要進展
      • 併購
      • 主要產品開發活動
      • 監管部門批准等
    • SWOT分析
  • Genetic Nutrition
  • NOW Foods
  • Enzymedica
  • AMYRA Biotech AG
  • KLAIRE LABS
  • Precigen
  • Takeda Pharmaceutical Company Limited
  • Similar data will be provided for each market player.

第 13 章：附錄

簡介目錄
Product Code: PH9054

The global gluten intolerance treatment market reached US$ 6.63 billion in 2024 and is expected to reach US$ 16.18 billion by 2032, growing at a CAGR of 11.8% during the forecast period 2024-2032.

Gluten intolerance, also known as non-celiac gluten sensitivity, is a condition where individuals experience symptoms such as abdominal discomfort, bloating, and fatigue after consuming gluten-containing foods, without having celiac disease or a wheat allergy. Unlike celiac disease, gluten intolerance does not cause damage to the small intestine but can still lead to significant discomfort and impact quality of life.

The gluten intolerance treatment market encompasses treatments aimed at alleviating symptoms and improving digestion, including dietary supplements, enzyme therapies, and emerging pharmaceutical options. As more people become aware of gluten intolerance and its symptoms, the market for supportive treatments and management solutions is expanding.

Market Dynamics: Drivers & Restraints

Growing Diagnosis Rates of Gluten-intolerance

Increasing diagnosis rates are expected to drive the gluten intolerance treatment market by leading to a larger patient population seeking medical interventions. As awareness of gluten intolerance and celiac disease grows among both healthcare providers and the public, more individuals are being accurately diagnosed. This rise in diagnoses translates to greater demand for effective treatment options, such as enzyme therapies, supplements, and emerging drug therapies.

Additionally, more diagnosed individuals are actively seeking solutions to manage their condition beyond a strict gluten-free diet, fueling the market for supportive treatments. As the number of diagnosed cases continues to rise, the market for gluten intolerance treatments is likely to expand significantly.

Dietary Preferences and Non-Medical Approaches

Dietary preferences and non-medical approaches are expected to hinder the gluten intolerance treatment market as many individuals prefer managing their condition through a gluten-free diet rather than relying on pharmaceutical interventions. The gluten-free diet is widely considered the primary and most effective way to control symptoms, which makes many patients less inclined to seek additional treatments such as enzyme supplements or medications. This reliance on dietary management limits the market demand for medical therapies.

Additionally, individuals may feel that non-medical approaches, such as lifestyle changes, are sufficient to manage their condition, reducing the urgency for new treatments and thus slowing market growth.

Segment Analysis

The global gluten intolerance treatment market is segmented based on treatment type, patient type, formulation, distribution channel, and region.

Type:

Nutritional supplements segment is expected to dominate the global gluten intolerance treatment market share

Nutritional supplements are expected to dominate the gluten intolerance treatment market due to their accessibility and growing popularity among patients seeking to manage symptoms alongside a gluten-free diet. Products like enzyme supplements and probiotics are gaining traction as they offer a convenient, non-invasive option to alleviate discomfort from accidental gluten exposure. Companies are focusing on developing these products which are increasingly gaining traction due to their increased safety and efficacy. For instance, in October 2024, AMYRA Biotech AG announced the peer-reviewed publication of its clinical proof-of-principle study with its lead product AMYNOPEP. AMYNOPEP is the first and only gluten-digesting enzyme combination that supports and enhances the activity of critical endogenous enzymes on the lining of the small intestine.

With increasing consumer awareness of the benefits of such supplements, the demand for these products is expanding, as they provide additional support without the need for prescription drugs. This trend positions nutritional supplements as a key segment in the market, driven by their ability to offer symptom relief and improve overall gut health for individuals with gluten intolerance.

Geographical Analysis

North America is expected to hold a significant position in the global gluten intolerance treatment market share

North America is expected to dominate the gluten intolerance treatment market due to high awareness, advanced healthcare infrastructure, and a large consumer base actively seeking treatment options. The U.S., in particular, leads in both diagnosis rates and adoption of gluten intolerance treatments, with a growing number of patients opting for enzyme supplements and emerging therapies.

Additionally, the presence of key pharmaceutical companies and the increasing availability of gluten-free products and treatments further strengthen North America's market share. The rising expansion of product availability in the region with rising innovative products is expected to contribute to the market growth in the region. For instance, in December 2024 GluteGuard, the first and only clinically proven product in Canada that helps to protect against the symptoms of accidental gluten ingestion is made available across the country. With the expansion of product expansion in the region, the market is expected to grow which contributes to the overall market growth. As awareness of gluten intolerance continues to rise, the region is likely to maintain its dominance in the treatment market.

Competitive Landscape

The major global players in the gluten intolerance treatment market include DSM-Firmenich, Genetic Nutrition, NOW Foods, Enzymedica, AMYRA Biotech AG, KLAIRE LABS, Precigen and Takeda Pharmaceutical Company Limited among others.

Why Purchase the Report?

  • Pipeline & Innovations: Reviews ongoing clinical trials, and product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
  • Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
  • Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
  • Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
  • Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
  • Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
  • Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
  • Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
  • Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
  • Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
  • Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
  • Post-market Surveillance: Uses post-market data to enhance product safety and access.
  • Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The Global Gluten Intolerance Treatment Market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2023

  • Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
  • Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
  • Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
  • Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
  • Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
  • Supply Chain: Distribution and Supply Chain Managers.
  • Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
  • Academic & Research: Academic Institutions.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Treatment Type
  • 3.2. Snippet by Patient Type
  • 3.3. Snippet by Formulation
  • 3.4. Snippet by Distribution Channel
  • 3.5. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Growing Diagnosis Rates of Gluten-intolerance
    • 4.1.2. Restraints
      • 4.1.2.1. Dietary Preferences and Non-Medical Approaches
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Patent Analysis
  • 5.5. Regulatory Analysis
  • 5.6. SWOT Analysis
  • 5.7. Unmet Needs

6. By Treatment Type

  • 6.1. Introduction
    • 6.1.1. Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 6.1.2. Market Attractiveness Index, By Treatment Type
  • 6.2. Dietary Management*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. Pharmaceuticals
  • 6.4. Nutritional Supplements
  • 6.5. Others

7. By Treatment Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 7.1.2. Market Attractiveness Index, By Treatment Type
  • 7.2. Pediatric*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Adult
  • 7.4. Geriatric

8. By Formulation

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Formulation
    • 8.1.2. Market Attractiveness Index, By Formulation
  • 8.2. Tablets*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Powders
  • 8.4. Liquid

9. By Distribution Channel

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.1.2. Market Attractiveness Index, By Distribution Channel
  • 9.2. Online Pharmacies*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Retail Pharmacies
  • 9.4. E-Commerce

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Formulation
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.7.1. U.S.
      • 10.2.7.2. Canada
      • 10.2.7.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Formulation
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.7.1. Germany
      • 10.3.7.2. U.K.
      • 10.3.7.3. France
      • 10.3.7.4. Spain
      • 10.3.7.5. Italy
      • 10.3.7.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Formulation
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.7.1. Brazil
      • 10.4.7.2. Argentina
      • 10.4.7.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Formulation
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.7.1. China
      • 10.5.7.2. India
      • 10.5.7.3. Japan
      • 10.5.7.4. South Korea
      • 10.5.7.5. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Formulation
    • 10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

Key Market Players

  • 12.1. DSM-Firmenich*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio
      • 12.1.2.1. Product Description
      • 12.1.2.2. Product Key Performance Indicators (KPIs)
      • 12.1.2.3. Historic and Forecasted Product Sales
      • 12.1.2.4. Product Sales Volume
    • 12.1.3. Financial Overview
      • 12.1.3.1. Company Revenue's
      • 12.1.3.2. Geographical Revenue Shares
      • 12.1.3.3. Revenue Forecasts
    • 12.1.4. Key Developments
      • 12.1.4.1. Mergers & Acquisitions
      • 12.1.4.2. Key Product Development Activities
      • 12.1.4.3. Regulatory Approvals etc.
    • 12.1.5. SWOT Analysis
  • 12.2. Genetic Nutrition
  • 12.3. NOW Foods
  • 12.4. Enzymedica
  • 12.5. AMYRA Biotech AG
  • 12.6. KLAIRE LABS
  • 12.7. Precigen
  • 12.8. Takeda Pharmaceutical Company Limited
  • Similar data will be provided for each market player.

LIST NOT EXHAUSTIVE

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us